leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 14:09:12 - browse：718

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： IVG is promising — but it won’t replace IVF quite yet

hotspot

WSS

With Roe v Wade overturned, abortion providers work to adapt

What will Novo Nordisk's VC do with its influx of cash?

Lawsuit highlights wrinkle for disputes over surprise medical bills

Medicare innovation center doesn’t save money, experts say

Flu, Covid vaccination rates decline, new survey data show

Caregivers of transplant patients call for more support, training

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

With Roe v Wade overturned, abortion providers work to adapt

What does generative AI mean for health care? We asked experts

Doulas covered by Medicaid under New York's new plan

Hepatitis C has a cure — but many Americans still lack access to it

Will an HIV vaccine ever be a reality?

United colonoscopy coverage change 'may cost lives,' doctors say

As JPM 2024 winds down, some health tech firms project optimism

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Risky weight loss products often used by teens globally, per study

hotspot

As JPM 2024 winds down, some health tech firms project optimism

Designating disabled people as health disparity population is crucial

Experts study whether long Covid risk adds up with each reinfection

Risky weight loss products often used by teens globally, per study

New menopause drug shows promise in relief for hot flashes

WHO recommends second malaria vaccine

knowledge

explore

hotspot

entertainment